Quality of life in cutaneous t-cell lymphoma patients treated with the Anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from MAVORIC.
Authors
Huen, APorcu, P
Hudgens, S
Quaglino, P
Cowan, Richard A
Floden, L
Tsianakas, A
Leoni, M
Dale, S
Duvic, M
Affiliation
MD Anderson Cancer Center, Houston, TexasIssue Date
2018-09
Metadata
Show full item recordCitation
Quality of life in cutaneous t-cell lymphoma patients treated with the Anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from MAVORIC. 2018, 18:S289 Clin Lymphoma Myeloma LeukJournal
Clinical Lymphoma Myeloma and LeukemiaDOI
10.1016/j.clml.2018.07.228Additional Links
https://linkinghub.elsevier.com/retrieve/pii/S2152265018309777Type
Meetings and ProceedingsLanguage
enISSN
21522650ae974a485f413a2113503eed53cd6c53
10.1016/j.clml.2018.07.228